Podcast
AI Access Brief Podcast
Hosted by Carl Haakon · EN
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
64episodes
Episodes
Newest firstAll episodes
Profit Warning, Approval, Settlement, Expansion
3d ago00:07:54Tap to summarizeEpisode 70 — 26 July 2026 Examining HCA's profit warning impact on US healthcare access, SubQ Leqembi approval HEOR implications, FTC insulin pricing settlement, and ICER scientific advice expansion. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →HCA Profit Warning & SubQ Leqembi
4d ago00:09:09Tap to summarizeEpisode 69 — 25 July 2026 Examining HCA's profit warning signaling U.S. healthcare access pressures, subcutaneous Leqembi's HEOR implications, FTC's insulin pricing settlement, and ICER's expanded scientific advice program. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →Profit Warnings & Pricing Scrutiny
5d ago00:07:35Tap to summarizeEpisode 68 — 24 July 2026 Hospital profit warnings and regulatory settlements signal systemic US healthcare access challenges, while new drug approvals and evidence frameworks evolve rapidly. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →US Access & Evidence Shifts
6d ago00:09:54Tap to summarizeEpisode 67 — 23 July 2026 Examining US healthcare system pressures, novel drug evidence challenges, insulin pricing enforcement, and Medicaid policy shifts shaping market access strategies. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →EMA RWE Pediatric Pilot & CMS Rebate Shift
1w ago00:08:14Tap to summarizeEpisode 66 — 22 July 2026 EMA launches pediatric RWE pilot for rare diseases; ISPOR 2026 highlights PRO framework shifts; CMS proposes Medicaid rebate changes; HTAI-IQVIA launches global RWE database. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →Profit Warnings, Insulin Settlements, and Leqembi
1w ago00:09:27Tap to summarizeEpisode 65 — 21 July 2026 Hospital system financial pressures, insulin pricing settlements, new Alzheimer's formulation approvals, and evolving HTA evidence strategies. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →HTA Evidence Evolution
1w ago00:09:43Tap to summarizeEpisode 64 — 20 July 2026 Examining RWE adoption challenges, digital therapeutics value assessment, orphan drug evidence standards, and AI's role in HTA methodologies. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →HTA Methodology Shifts & Pricing Pressures
1w ago00:06:46Tap to summarizeEpisode 63 — 19 July 2026 Examining evolving HTA methodologies, CMS coverage shifts, patent settlement impacts, and NICE's equity framework. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →HTA Methodology Shifts & FDA Accelerated Approvals
2w ago00:08:56Tap to summarizeEpisode 62 — 18 July 2026 Examining evolving HTA frameworks in Asia-Pacific, Canada's pricing reforms, RWE integration barriers in Latin America, and gene therapy evidence strategies in Asia. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →HTA & RWE Shifts
2w ago00:11:17Tap to summarizeEpisode 20 — 17 July 2026 Examining CMS CAR-T coverage implications, FDA's RWE guidance for accelerated approvals, ISPOR's value pricing pivot, and NICE's ultra-rare disease framework updates. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast
Transcribe →